Jazz Pharmaceuticals Files Second Quarter 10-Q Ahead of Earnings Call
The Ireland-based biopharmaceutical company submitted its quarterly report to the SEC as it prepares to release Q2 2026 results.
Quarterly Filing Precedes Earnings Release
Jazz Pharmaceuticals plc filed its quarterly report on Form 10-Q with the Securities and Exchange Commission on August 3, according to SEC EDGAR filings. The Ireland-domiciled biopharmaceutical company, which carries a market capitalization of approximately $16 billion, closed at $252.86 in its most recent trading session.
The 10-Q filing comes as the company is scheduled to report its second quarter 2026 results later today, followed by an earnings call with analysts and investors, according to MarginX data.
Recent Insider Activity
MarginX data shows recent insider transactions at the company. CEO Bruce C. Cozadd sold 6,000 shares, while executives Samantha Pearce and Renee D. Gala had shares withheld for tax purposes totaling 2,527 and 4,835 shares, respectively. Tax withholding transactions typically occur in connection with the vesting of equity compensation awards.
Broader Market Context
The earnings release arrives as investors prepare for the Federal Reserve's next policy decision on September 16, when the Federal Open Market Committee will announce its rate decision along with updated economic projections. Another FOMC meeting is scheduled for October 28, according to MarginX data.
Jazz Pharmaceuticals specializes in developing and commercializing therapies for sleep disorders, oncology, and other conditions. The company's quarterly filings provide investors with detailed financial statements, management discussion and analysis, and disclosures about material changes to the business during the reporting period.
The 10-Q form is a comprehensive report that publicly traded companies must file with the SEC for the first three quarters of each fiscal year, containing unaudited financial statements and updates on business operations, risks, and legal proceedings.
Investors and analysts will be looking to the earnings call for management commentary on the quarter's performance and any updates to the company's full-year guidance.
This article was generated by MarginX from public news on 2026-08-03. It is not investment advice.